A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma

Autor: Flümann, Ruth, Nieper, Pascal, Lohmann, Tim, Kisis, Ilmars, Peifer, Martin, Abedpour, Nima, Thomas, Roman, Kochanek, Moritz, Pelzer, Benedikt, Beleggia, Filippo, Buettner, Reinhard, Lohneis, Philipp, Persigehl, Thorsten, Hallek, Michael, Calado, Dinis Pedro, Pasqualucci, Laura, von Tresckow, Bastian, Chapuy, Björn, Jachimowicz, Ron, Reinhardt, Christian, Knittel, Gero
Zdroj: Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p712-712, 1p
Abstrakt: Diffuse large B cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. Both biologically and clinically, DLBCL represents a highly heterogeneous disease. DLBCL has been subdivided into germinal center B cell (GCB)-like and activated B cell (ABC)-like DLBCL, on the basis of gene expression profiling, which separates DLBCL according to the presumed cell of origin (COO). This COO-based classifier distinguishes sub-entities displaying distinct biological features, pathogenesis and clinical response to frontline therapy.
Databáze: Supplemental Index